ID
19933
Beskrivning
The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS. Documentation process: This form is to be obtained in Baseline Week 0, week 12, week 36, week 60, week 72, week 84, week 96, week 108 and week 120.
Nyckelord
Versioner (3)
- 2017-01-30 2017-01-30 -
- 2017-01-31 2017-01-31 -
- 2017-01-31 2017-01-31 -
Uppladdad den
31 januari 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Antibody and PK Pre-Dose CRFs Multiple Sclerosis Tysabri NCT00027300
Antibody and PK Pre-Dose CRFs Multiple Sclerosis Tysabri NCT00027300
Similar models
Antibody and PK Pre-Dose CRFs Multiple Sclerosis Tysabri NCT00027300
C1516698 (UMLS CUI [1,2])
C0031327 (UMLS CUI [1,2])